Plain-English translation of NCT03938987 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new type of cancer treatment called CAR T-cell therapy, where doctors take your own immune cells, engineer them in a lab to recognize and attack cancer cells, and then give them back to you. The treatment is designed for patients with aggressive lymphoma or acute lymphoblastic leukemia (ALL) that has come back or stopped responding to standard therapies. Researchers want to find the best dose of these engineered cells and see how well they work.
Many patients with advanced lymphoma and leukemia run out of effective treatment options after standard therapies stop working. This medication represents a new approach that uses the body's own immune system to fight cancer, and this trial will help doctors understand the safest and most effective way to use it.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy over three days to prepare your body. On day zero, you'll receive an infusion of your engineered immune cells through an IV. Before treatment, doctors will collect some of your blood cells, send them to a lab for processing and engineering, and grow them over several weeks. You'll need to be available for regular follow-up visits and monitoring to track how well the treatment works and watch for any side effects. The trial includes both a dose-finding phase and an expansion phase to confirm the best dose.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada